New Frontier Healthcare/United Family Healthcare Deepens Strategic Partnership with Warburg Pincus; 120 Million Equity Acquisition Finalized, China Resources Expands Portfolio

New Wind Healthcare/United Family Healthcare Deepens Strategic Cooperation with Warburg Pincus

Recently, New Frontier Health/United Family Healthcare, a benchmark enterprise in China's high-end private medical services, announced a deepened strategic partnership with Warburg Pincus, a global leader in private equity investment. The latter has further increased its stake in United Family Healthcare. This upgraded cooperation demonstrates Warburg Pincus' confidence in the development strategy of United Family Healthcare and will further help it establish its leading position in China’s private healthcare industry. After the completion of the transaction, Warburg Pincus will become an important shareholder of United Family Healthcare and secure a seat on the board of directors. (Source: Arterial Network)

120 Million Equity Acquisition Completed, CR Land's Territory +1

On January 26, 2025, Zhenyuan Pharmaceutical released a company announcement stating that, according to the resolution passed at the board’s interim meeting on the proposal "Regarding the Wholly-Owned Subsidiary Zhenyuan Pharmaceutical Implementing Capital Increase and Share Expansion via Public Listing to Introduce Strategic Investors," it was decided to implement a capital increase and share expansion for its wholly-owned subsidiary, Shaoxing Zhenyuan Pharmaceutical Co., Ltd. (hereinafter referred to as "Zhenyuan Pharmaceutical"), through public listing at the Shaoxing Property Rights Exchange Co., Ltd. (Zhejiang Property Rights Exchange Shaoxing Branch, hereinafter referred to as the "Exchange"). A leading pharmaceutical commercial enterprise will be introduced as a strategic investor. By strengthening business integration and cooperation with leading enterprises, this move aims to enhance the company's future profitability and accelerate the transformation of its business structure. (Source: Sina Finance)

BEIJING JYTON AND KANNEL MEDICAL TECH.CO.,LTD. Assists in the Approval and Market Launch of the World's First Gastrointestinal Endoscopy Surgical Robot

BEIJING JYTON AND KANNEL MEDICAL TECH.CO.,LTD. Assists Robo Medical’s World’s First Digestive Endoscopy Surgical Robot in Successful Approval and Market Launch; the Robot Employs Advanced Design for Precise Surgical Control, Enhancing Efficiency and Reducing Risks, Providing Strong Technical Support for Early Gastrointestinal Cancer Diagnosis and Treatment. BEIJING JYTON AND KANNEL MEDICAL TECH.CO.,LTD. Empowers Technological Innovation with Professional Scientific Services, Demonstrating Full-Chain Service Capabilities. (Source: Arterial Network)

Organon Launches Rogaine® Minoxidil Topical Solution, AliHealth First to Debut Online

Recently, the over-the-counter hair loss treatment drug, Pofasheng® Minoxidil Lotion, launched by Organon China, has debuted on AliHealth's online pharmacy. With the advancement of "Internet + medical health" and digital healthcare, convenient and efficient online drug purchasing has become a new habit for users in China. The shift of health consumption to online platforms is making e-commerce a core growth driver in the pharmaceutical retail market. AliHealth has become the preferred platform for the debut of new drugs from various brands. Recently, several significant new drugs have successively launched on AliHealth’s online pharmacy, including 0.01% Atropine Sulfate Eye Drops by Xingqi Eye Medicine, Delijing®, an innovative drug independently developed by Daiichi Sankyo, Marvelon, a combined oral contraceptive by Organon, and Yisupagruptide α Injection independently developed by Silverno Medical. (Source: AliHealth)

Fire Eye Crystal Completes Nearly RMB10 Million Angel Round Financing

Shenzhen Huoyanjingjing Medical Technology Co., Ltd. (referred to as "Huoyanjingjing"), which specializes in the digital optometry field, announced that it has completed an angel round of financing worth nearly ten million yuan, exclusively invested by Times Bole. This round of financing will accelerate Huoyanjingjing's R&D iteration and market expansion in the XR intelligent medical field of optometry, promoting myopia prevention and control technology for children and adolescents into a new intelligent stage. (Source: Arterial Network)

Insilico Medicine Completes $110 Million Series E Financing

On March 13, Insilico Medicine, a biopharmaceutical technology company driven by generative artificial intelligence, announced the completion of its $110 million Series E financing round. The round was jointly led by a private equity fund under Value Partners Group (HKG: 0806), one of Asia's largest independent asset management companies, along with Pudong Venture Capital, Pudong Development Group, Xichang Venture Capital, and Yixing State-owned Assets Control. This financing round also attracted participation from new investors specializing in industry and technology sectors and received support from existing investors. (Source: Arterial Network)

Weimei Health Completes A-Round Hundred-Million-Level Financing

Weimei Health, which focuses on innovative applications of artificial intelligence in the healthcare field, has recently completed its Series A round of financing worth hundreds of millions. This round of financing was led by Redding Capital, with participation from Weimei Health's angel round investors. The funds will be used for the research and development and iterative evolution of Weimei Health’s “Singularity Medical Inquiry” large medical model, strengthening algorithm research in specific medical fields, upgrading the service network system across China, and expanding Weimei Health's market advantage in county-level and grassroots AI healthcare sectors. (Source: Arterial Network)

Unique Medical Completes Nearly 150 Million Yuan in Series C Financing

Recently, Suzhou Wushuang Medical Equipment Co., Ltd. ("Wushuang Medical") announced the completion of a nearly 150 million yuan Series C financing round. This round was led by Tasly Capital, with continued support from existing shareholders Qiming Venture Partners, SND Holdings, and Kangyu Capital. The funds raised will be used for the company's new product development and commercialization efforts. (Source: Arterial Network)

91 Cases! The 2024 Investment and Financing Annual Report on Synthetic Biology is Released

Investment and Financing in the Synthetic Biology Field Continue to Heat Up in 2024, Nearly Doubling Compared to 2023. According to statistics from Junyi Capital, the number of financing deals in China's primary market for synthetic biology reached a significant leap of 91 in 2024, up sharply by 61.4% compared to 57 deals in 2023. This data vividly reflects that the synthetic biology sector is attracting increasing attention from more capital, becoming a popular track in the investment community, demonstrating strong confidence in the future development potential of this field. (Source: Sina Finance)

177 Varieties Proposed for Inclusion in the National Reimbursement Drug List for Outpatient Coordinated Payment

On March 11, the Hainan Provincial Medical Insurance Bureau issued an announcement to once again solicit public opinions on the "Notice on Separate Outpatient Coordinated Payment for Some Nationally Negotiated Drugs (Draft for Comments)." This time, it is proposed to include 177 varieties into the separate outpatient coordinated payment scope for nationally negotiated drugs. The public can submit comments and suggestions in writing or by email to the Medical and Pharmaceutical Services Management Department of the Provincial Medical Insurance Bureau before 17:00 on March 13, 2025. (Source: Medical Insurance Bureau)